Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Severe Acute Lung Injury Related to COVID-19 Infection : A Review and the Possible Role for Escin

© 2020, The American College of Clinical Pharmacology.

Acute lung injury (ALI) represents the most severe form of the viral infection sustained by coronavirus disease 2019 (COVID-19). Today, it is a pandemic infection, and even if several compounds are used as curative or supportive treatment, there is not a definitive treatment. In particular, antiviral treatment used for the treatment of several viral infections (eg, hepatitis C, HIV, Ebola, severe acute respiratory syndrome-coronavirus) are today used with a mild or moderate effect on the lung injury. In fact, ALI seems to be related to the inflammatory burst and release of proinflammatory mediators that induce intra-alveolar fibrin accumulation that reduces the gas exchange. Therefore, an add-on therapy with drugs able to reduce inflammation, edema, and cell activation has been proposed as well as a treatment with interferon, corticosteroids or monoclonal antibodies (eg, tocilizumab). In this article reviewing literature data related to the use of escin, an agent having potent anti-inflammatory and anti-viral effects in lung injury, we suggest that it could represent a therapeutic opportunity as add-on therapy in ALI related to COVID-19 infection

Year of Publication: 2020
Contained in: Journal of clinical pharmacology Vol. 60, No. 7 (2020), p. 815-825
All journal articles: Search for all articles in this journal
Language: English
Contributors: Gallelli, Luca | Author
Zhang, Leiming
Wang, Tian
Fu, Fenghua
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: 6805-41-0
COVID-19
Journal Article
Review
acute lung injury
coronavirus-2
escin
pneumonia
Additional Keywords: Acute Lung Injury
Anti-Inflammatory Agents
Antiviral Agents
Betacoronavirus
Coronavirus Infections
Drug Therapy, Combination
Escin
Humans
Immunologic Factors
Inflammation Mediators
Lung
Pandemics
Pneumonia, Viral
ISSN: 1552-4604
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 06.07.2020
Date Revised 06.07.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32441805
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1002/jcph.1644
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 04292nma a2200865 c 4500
001 NLM311114032
003 DE-601
005 20200715033330.0
007 cr uuu---uuuuu
008 200522s2020 000 0 eng d
024 7 |a 10.1002/jcph.1644  |2 doi 
028 5 2 |a pubmed20n1257.xml 
035 |a (DE-599)NLM32441805 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Gallelli, Luca 
245 1 0 |a Severe Acute Lung Injury Related to COVID-19 Infection  |h Elektronische Ressource  |b A Review and the Possible Role for Escin 
300 |a Online-Ressource 
500 |a Date Completed 06.07.2020 
500 |a Date Revised 06.07.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a © 2020, The American College of Clinical Pharmacology. 
520 |a Acute lung injury (ALI) represents the most severe form of the viral infection sustained by coronavirus disease 2019 (COVID-19). Today, it is a pandemic infection, and even if several compounds are used as curative or supportive treatment, there is not a definitive treatment. In particular, antiviral treatment used for the treatment of several viral infections (eg, hepatitis C, HIV, Ebola, severe acute respiratory syndrome-coronavirus) are today used with a mild or moderate effect on the lung injury. In fact, ALI seems to be related to the inflammatory burst and release of proinflammatory mediators that induce intra-alveolar fibrin accumulation that reduces the gas exchange. Therefore, an add-on therapy with drugs able to reduce inflammation, edema, and cell activation has been proposed as well as a treatment with interferon, corticosteroids or monoclonal antibodies (eg, tocilizumab). In this article reviewing literature data related to the use of escin, an agent having potent anti-inflammatory and anti-viral effects in lung injury, we suggest that it could represent a therapeutic opportunity as add-on therapy in ALI related to COVID-19 infection 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Review  |2 gnd 
653 2 |a Acute Lung Injury  |6 D055371  |a *etiology  |6 Q000209  |a physiopathology  |6 Q000503 
653 2 |a Anti-Inflammatory Agents  |6 D000893  |a therapeutic use  |6 Q000627 
653 2 |a Antiviral Agents  |6 D000998  |a therapeutic use  |6 Q000627 
653 2 |a Betacoronavirus  |6 D000073640 
653 2 |a Coronavirus Infections  |6 D018352  |a *complications  |6 Q000150  |a *drug therapy  |6 Q000188  |a physiopathology  |6 Q000503 
653 2 |a Drug Therapy, Combination  |6 D004359 
653 2 |a Escin  |6 D004928  |a administration & dosage  |6 Q000008  |a pharmacology  |6 Q000494  |a *therapeutic use  |6 Q000627 
653 2 |a Humans  |6 D006801 
653 2 |a Immunologic Factors  |6 D007155  |a therapeutic use  |6 Q000627 
653 2 |a Inflammation Mediators  |6 D018836  |a metabolism  |6 Q000378 
653 2 |a Lung  |6 D008168  |a pathology  |6 Q000473 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a *complications  |6 Q000150  |a *drug therapy  |6 Q000188  |a physiopathology  |6 Q000503 
655 7 |a COVID-19  |2 gnd 
655 7 |a acute lung injury  |2 gnd 
655 7 |a coronavirus-2  |2 gnd 
655 7 |a escin  |2 gnd 
655 7 |a pneumonia  |2 gnd 
655 7 |a Anti-Inflammatory Agents  |2 gnd 
655 7 |a Antiviral Agents  |2 gnd 
655 7 |a Immunologic Factors  |2 gnd 
655 7 |a Inflammation Mediators  |2 gnd 
655 7 |a Escin  |2 gnd 
655 7 |a 6805-41-0  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Review 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a acute lung injury 
689 1 2 |a coronavirus-2 
689 1 3 |a escin 
689 1 4 |a pneumonia 
689 1 |5 DE-601 
689 2 0 |a Anti-Inflammatory Agents 
689 2 1 |a Antiviral Agents 
689 2 2 |a Immunologic Factors 
689 2 3 |a Inflammation Mediators 
689 2 4 |a Escin 
689 2 5 |A r  |a 6805-41-0 
689 2 |5 DE-601 
700 1 |a Zhang, Leiming 
700 1 |a Wang, Tian 
700 1 |a Fu, Fenghua 
773 0 8 |i in  |t Journal of clinical pharmacology  |g Vol. 60, No. 7 (2020), p. 815-825  |q 60:7<815-825  |w (DE-601)NLM000005584  |x 1552-4604 
856 4 1 |u http://dx.doi.org/10.1002/jcph.1644  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 60  |j 2020  |e 7  |b 06  |c 07  |h 815-825